This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This is not a full-text translation of the original paper. It is an independently organized detailed introduction based on the public article and bibliographic information, distinguishing what was chemically identified, the experimental systems in which effects were observed, and where inference to people begins. The paper identified a frog used in hunting-related practices near the Brazil–Peru border as Phyllomedusa bicolor and reported a new peptide, adenoregulin, from its skin secretion.
Although the article includes ethnographic background, its experiments center on chemical analysis of the secretion, receptor binding, and mouse behavior. It did not compare treatment outcomes or hunting performance among human ritual participants. The description of cultural practice must not be conflated with basic pharmacology of an isolated peptide.
Study design
The researchers fractionated skin secretion and determined the amino-acid sequence of adenoregulin using mass spectrometry and Edman degradation. The reported mature peptide contained 33 residues. Chromatographic characteristics of the natural and synthetic peptides did not completely match, leaving open the possibility that the natural form contained a D-amino acid.
They then tested effects on agonist binding to the A1 adenosine receptor and observed inhibitory activity from other fractions of the secretion. Fractions and related substances including adenoregulin, sauvagine, and opioid peptides were also studied in mice, and behavioral changes were described. The design did not experimentally administer whole secretion to humans.
Content
The secretion contained not only adenoregulin but also vasoactive peptides, opioid peptides, and constituents that enhanced or inhibited receptor binding. This shows that the effect of whole secretion cannot be reduced to 1 molecule. One fraction may enhance receptor binding while another acts in the opposite direction, with absorption, degradation, and distribution adding further effects in the body.
The finding that adenoregulin enhanced binding of an A1-receptor agonist does not directly mean it improved human energy, mood, endurance, or cardiac function. A receptor-binding assay examines molecular interactions; it is not a clinical outcome.
Results
The principal achievement was identifying a new 33-residue peptide from P. bicolor, naming it adenoregulin, and observing that it enhanced agonist binding at the A1 adenosine receptor. The same secretion also contained peptides that inhibited binding. Differences between natural and synthetic forms show that the structure had not been completely resolved at the time.
Multiple secretion constituents affected mouse behavior. The paper discussed the possibility that these constituents contributed to acute responses described in humans, but did so within the inferential scope of “presumably.” It did not measure each constituent’s actual concentration, interaction, or causal contribution in human experience.
Limitations
This was chemical-identification, receptor, and animal research, not a human clinical trial. Parts of the stereochemistry of natural adenoregulin were unresolved, and the secretion contains constituents with opposing effects. Conditions involving extracted and fractionated material differ from absorption of whole secretion through a burn wound.
Mouse behavior cannot be directly extrapolated to hunting ability, spiritual meaning, or disease improvement. Descriptions involving people came from existing accounts of practice and did not use standardized scales, control groups, or measured amounts. This was also not a study covering modern safety cases.
Safety
The coexistence of multiple vasoactive, opioid, and receptor-modulating peptides demonstrates that whole secretion is a complex pharmacologic exposure. Identification of a new peptide cannot become evidence for the safety of whole secretion or self-administration.
The study did not establish a safe amount, administration method, contraindications, or balance of benefit and risk in humans. Candidate molecules in basic research and medical evaluation of a ritual must be treated separately.
Source and rights
Original source: Daly JW, et al. Frog secretions and hunting magic in the upper Amazon: identification of a peptide that interacts with an adenosine receptor. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(22):10960–10963. DOI: 10.1073/pnas.89.22.10960. PMID 1438301; PMCID PMC50462.
A digitized full text is available in PMC, but it is not in the NCBI Open Access Subset and no explicit Creative Commons reuse license was identified. This page is an independent detailed introduction and does not reproduce the source text, page images, tables, or sequence figures.